tetano
Editor, Senior Moderator
J Thorac Oncol
. 2021 Nov 2;S1556-0864(21)03286-X.
doi: 10.1016/j.jtho.2021.10.015. Online ahead of print.
Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses
Valérie Gounant[SUP] 1 [/SUP], Valentine Marie Ferré[SUP] 2 [/SUP], Ghassen Soussi[SUP] 1 [/SUP], Charlotte Charpentier[SUP] 2 [/SUP], Héloïse Flament[SUP] 3 [/SUP], Nadhira Fidouh[SUP] 2 [/SUP], Gilles Collin[SUP] 2 [/SUP], Céline Namour[SUP] 1 [/SUP], Sandra Assoun[SUP] 1 [/SUP], Alexandra Bizot[SUP] 1 [/SUP], Zohra Brouk[SUP] 1 [/SUP], Eric Vicaut[SUP] 4 [/SUP], Luis Teixeira[SUP] 5 [/SUP], Diane Descamps[SUP] 2 [/SUP], Gérard Zalcman[SUP] 6 [/SUP]
Affiliations
Abstract
Hypothesis: Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, it is still unknown whether they would develop a protective anti-spike antibody response following vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to SARS-CoV2 vaccine in thoracic cancer patients.
Methods: SARS-CoV2-spike antibodies were measured using Abbot ARCHITECT SARS-CoV-2 IgG immunoassay, prior to first injection of BNT162b2 mRNA vaccine, as well as at Week 4, and two-to-sixteen weeks after second vaccine dose. The factors associated with antibody response were analyzed.
Results: Overall, 306 patients, with a median age of 67.0 years (IQR=58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of 269 serological results available beyond Day 14 post-second vaccine dose, 17 (6.3%) were still negative (<50 AU/mL) (arbitrary units/mL), while 34 (11%) were <300 AU/mL (12.5[SUP]th[/SUP] percentile). In multivariate analysis, only age and chronic corticosteroid treatment were significantly associated with a lack of immunization. Thirty patients received a third vaccine dose, with only three patients showing persistent negative serology thereafter, whereas the others demonstrated clear seroconversion.
Conclusion: SARS-CoV2 vaccines were shown to be efficient in thoracic cancer patients, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in a 88% immunization rate.
Keywords: COVID-19; Sars-CoV2 vaccination; antibody response; chemotherapy; immune checkpoint inhibitors; lung cancer; mRNA vaccine.
. 2021 Nov 2;S1556-0864(21)03286-X.
doi: 10.1016/j.jtho.2021.10.015. Online ahead of print.
Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses
Valérie Gounant[SUP] 1 [/SUP], Valentine Marie Ferré[SUP] 2 [/SUP], Ghassen Soussi[SUP] 1 [/SUP], Charlotte Charpentier[SUP] 2 [/SUP], Héloïse Flament[SUP] 3 [/SUP], Nadhira Fidouh[SUP] 2 [/SUP], Gilles Collin[SUP] 2 [/SUP], Céline Namour[SUP] 1 [/SUP], Sandra Assoun[SUP] 1 [/SUP], Alexandra Bizot[SUP] 1 [/SUP], Zohra Brouk[SUP] 1 [/SUP], Eric Vicaut[SUP] 4 [/SUP], Luis Teixeira[SUP] 5 [/SUP], Diane Descamps[SUP] 2 [/SUP], Gérard Zalcman[SUP] 6 [/SUP]
Affiliations
- PMID: 34798306
- DOI: 10.1016/j.jtho.2021.10.015
Abstract
Hypothesis: Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, it is still unknown whether they would develop a protective anti-spike antibody response following vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to SARS-CoV2 vaccine in thoracic cancer patients.
Methods: SARS-CoV2-spike antibodies were measured using Abbot ARCHITECT SARS-CoV-2 IgG immunoassay, prior to first injection of BNT162b2 mRNA vaccine, as well as at Week 4, and two-to-sixteen weeks after second vaccine dose. The factors associated with antibody response were analyzed.
Results: Overall, 306 patients, with a median age of 67.0 years (IQR=58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of 269 serological results available beyond Day 14 post-second vaccine dose, 17 (6.3%) were still negative (<50 AU/mL) (arbitrary units/mL), while 34 (11%) were <300 AU/mL (12.5[SUP]th[/SUP] percentile). In multivariate analysis, only age and chronic corticosteroid treatment were significantly associated with a lack of immunization. Thirty patients received a third vaccine dose, with only three patients showing persistent negative serology thereafter, whereas the others demonstrated clear seroconversion.
Conclusion: SARS-CoV2 vaccines were shown to be efficient in thoracic cancer patients, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in a 88% immunization rate.
Keywords: COVID-19; Sars-CoV2 vaccination; antibody response; chemotherapy; immune checkpoint inhibitors; lung cancer; mRNA vaccine.